Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

676 articles

Research Review

Showing 1–2 of 2 articles · Keyword: Triple negative breast cancer Clear keyword

Advanced pharmaceutical bulletin2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Effect of Exosome-loaded hsa-miR-203a-3p on Triple Negative Breast Cancer Cell Viability, Migration, and Gene Targets: In Silico and In Vitro Study

Ardiansyah Sa, Noficandra H, Satriyo Pb, Nugrahaningsih Daa, Haryana Sm

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking targeted therapy options. MicroRNA-based therapy, particularly hsa-miR-203a-3p, has shown tumor-suppressive potential; however, an effective delivery system is required to enhance its stability and cellular uptake. Exosomes represent…

Read the article

Drug development research2026ResearchNon-viral Gene DeliveryDrug Delivery

2. Preclinical Evaluation of cRGD-Functionalized Lipid-Polymer Hybrid Nanocarriers for Anti-VEGF Gene Therapy in Triple-Negative Breast Cancer

Cesur Ergun B, Demir-Dora D

Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes owing to its high metastatic potential and the absence of effective molecularly targeted therapies. Although cRGD-functionalized nanocarriers have been extensively investigated for TNBC treatment, most reported systems…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.